

Study of investigational REGN5668 + cemiplimab or ubamatamab in patients with recurrent ovarian cancer



Primary Objective: evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of REGN5668 with cemiplimab or ubamatamab in patients with recurrent ovarian cancer



PATIENTS WITH OVARIAN CANCER (N≈326)

OPEN LABEL INTERVENTION

Module 1

REGN5668 (IV) + cemiplimab (IV)
Q1W Q3W

Module 2

REGN5668 (IV) + ubamatamab (IV)
Q1W Q1W

Primary Endpoints

Dose escalation: Safety, tolerability, and pharmacokinetics

Dose expansion: Objective response rate^a

Secondary Endpoints

Dose escalation: Objective response rate^b, efficacy, and immunogenicity

Dose expansion: Safety, pharmacokinetics, efficacy, and immunogenicity



FIND OUT MORE

Scan here to find out more about this study at <https://clinicaltrials.gov/ct2/show/NCT04590326>

This information is intended for investigators interested in open clinical trials.

The use of REGN5668 + cemiplimab or ubamatamab described herein is investigational and has not been evaluated by any regulatory authority.

Please see full prescribing information in your country for cemiplimab.

^aAssessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. ^bAssessed using immune-based RECIST (iRECIST).
IV, intravenous; N, number of patients; Q1W, administered every week; Q3W, administered every three weeks.

NCT04590326**PHASE 1/2 ENROLLING****REGN5668****An Investigational MUC16xCD28 Bispecific Antibody**Designed to bridge MUC16 on cancer cells with CD28 on T-cells¹**UBAMATAMAB****OR****CEMPIPLIMAB****An Investigational MUC16xCD3 Bispecific Antibody**Designed to bridge MUC16 on cancer cells with CD3 on T cells²**An Investigational, Fully Human PD-1 Monoclonal Antibody**Designed to block cancer cells from using the PD-1 pathway to suppress T-cell activation³**SELECTED INCLUSION CRITERIA^a****0 or 1**

ECOG PS 0 or 1



Adequate organ and bone marrow function



Confirmed diagnosis of advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy



Life expectancy of at least 3 months

Serum CA-125 level $\geq 2\times$ ULN**SELECTED EXCLUSION CRITERIA^a**

Prior anti-cancer immunotherapy



Any condition that requires ongoing/continuous corticosteroid therapy



Recent treatment with PD-1/PDL-1 therapy or MUC16-targeted therapy



Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments



Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence



Untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression

For more information, visit www.clinicaltrials.gov or please call 844 REGN-MID.**NCT04590326**<https://clinicaltrials.gov/ct2/show/NCT04590326>**This information is intended for investigators interested in open clinical trials.****The use of REGN5668 + cemiplimab or ubamatamab described herein is investigational and has not been evaluated by any regulatory authority.****Please see full prescribing information in your country for cemiplimab.**^aInclusion/exclusion criteria include a summary of selected criteria. Please review the complete study design on [clinicaltrials.gov](https://www.clinicaltrials.gov) for complete details.

CA, cancer antigen; CD, cluster of differentiation; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; MUC16, mucin 16; PD-1, programmed cell death 1; ULN, upper limit of normal.

Current per [clinicaltrials.gov](https://www.clinicaltrials.gov) as of October 4, 2023.1. National Cancer Institute Drug Dictionary: REGN5668. Available at: <https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-muc16-cd28-bispecific-antibody-regn5668> (Accessed May 2023).2. Winer et al, *J Clin Oncol*, 2021;39:TPS5602. 3. Markham A, Duggan S. *Drugs*. 2018;78(17):1841-1846. TPS5602.

REGN4018-EM-0003 October 2023.

©2023 Regeneron Pharmaceuticals, Inc. All rights reserved.

REGENERON
MEDICAL AFFAIRS